Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
about
Siltuximab (CNTO 328): a promising option for human malignanciesSiltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms: 2015 SH/EAHP Workshop Report-Part 3.
P2860
Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Patient-reported Outcomes for ...... ontrolled Study of Siltuximab.
@ast
Patient-reported Outcomes for ...... ontrolled Study of Siltuximab.
@en
type
label
Patient-reported Outcomes for ...... ontrolled Study of Siltuximab.
@ast
Patient-reported Outcomes for ...... ontrolled Study of Siltuximab.
@en
prefLabel
Patient-reported Outcomes for ...... ontrolled Study of Siltuximab.
@ast
Patient-reported Outcomes for ...... ontrolled Study of Siltuximab.
@en
P2093
P2860
P50
P1476
Patient-reported Outcomes for ...... ontrolled Study of Siltuximab.
@en
P2093
Alexander Fosså
Corey Casper
James Cavet
Jessica Vermeulen
Kai Fai Ho
Margaret Rothman
Nikhil Munshi
Raymond S Wong
Sarah Fleming
P2860
P2888
P304
P356
10.1007/S40271-015-0120-5
P577
2015-01-01T00:00:00Z